The molecular processes governing hematopoiesis involve the interplay between lineage-specific transcription factors and a series of epigenetic tags, including DNA methylation and covalent histone tail modifications, such as acetylation, methylation, phosphorylation, SUMOylation and ubiquitylation. These post-translational modifications, which collectively constitute the 'histone code', are capable of affecting chromatin structure and gene transcription and are catalysed by opposing families of enzymes, allowing the developmental potential of hematopoietic stem cells to be dynamically regulated. The essential role of these enzymes in regulating normal blood development is highlighted by the finding that members from all families of chromatin regulators are targets for dysregulation in many hematological malignancies, and that patterns of histone modification are globally affected in cancer as well as the regulatory regions of specific oncogenes and tumor suppressors. The discovery that these epigenetic marks can be reversed by compounds targeting aberrant transcription factor/co-activator/co-repressor interactions and histone-modifying activities, provides the basis for an exciting field in which the epigenome of cancer cells may be manipulated with potential therapeutic benefits. Oncogene (2007) 26, 6697-6714; doi:10.1038/sj.onc.1210755 Keywords: hematopoiesis; epigenetics; histone code; methylation; leukemia; acetylation
Overview
Hematopoiesis is a dynamic process in which pluripotent, hematopoietic stem cells (HSCs) give rise to all the lineages of the blood, including T and B cells which constitute the lymphoid lineage, and neutrophils, eosinophils, basophils, monocytes, macrophages, megakaryocytes, platelets and erythrocytes which comprise the myeloid lineage (Zhu and Emerson, 2002) . This process involves the coordination of signal transduction pathways, which are responsive to extracellular stimuli, and transcriptional networks affecting gene expression, such that the ultimate fate of the active HSC pool is linked to the functional needs of the organism. The regulation of gene transcription is critically mediated by the binding of sequence-specific transcription factors to target gene promoters and enhancers. These factors flag those regions of the genome destined to be transcribed into RNA, and work in part by recruitment of basal transcription factors and RNA polymerase II to target genes. Sequence-specific DNA-binding factors also recruit cofactors to gene regulatory regions, many of which are part of multiprotein enzymatic complexes which facilitate or inhibit gene transcription by modification of chromatin, the protein-bound state of DNA present in the cell (Bottardi et al., 2007) . Modulation of gene expression by chromatin modification is termed 'epigenetic' regulation, and refers to stable and heritable changes in gene expression that do not involve DNA sequence alterations. Such changes include DNA methylation, nucleosomal histone modifications, post-translational modifications and antisense miRNA silencing.
Nucleosomal histones: substrates for epigenetic modification
The organization of DNA into higher order structures, or nucleosomes, is a central component to epigenetic gene regulation. Each nucleosome, which represents the basic repeating unit of chromatin, consists of 147 bp of DNA wrapped around a core of eight histones including two molecules each of H2A, H2B, H3 and H4 (Luger et al., 1997) . Individual nucleosomes are joined to each other by the linker histone H1 and a short length of DNA (B200740 bp) to yield the 10 nm fiber, which may be further compacted into a helical structure referred to as a 30 nm fiber via interactions between the more variable, flexible histone tails, which protrude from the nucleosomal disk. The concept of a 'histone code' was proposed following the discovery of specific post-translational covalent modifications of these histone tails by acetylation, methylation, phosphorylation, glycosylation, SUMOylation and ubiquitylation. Such modifications act in a concerted manner to induce structural changes in the chromatin fiber and to regulate the accessibility of transcription factors to gene regulatory sequences, ADP ribosylate affecting gene expression (Jenuwein and Allis, 2001 ). There are a vast number of potential combinations of chromatin modifications that can be displayed by histones but several generalizations can be made. Transcribed genes may be present in nucleosome-free regions that are highly accessible to transcription factors, or in regions of chromatin that tend to be hyperacetylated through the action of histone acetyltransferases (HATs). By contrast, heterochromatic regions, generally silent in terms of gene expression, tend to be hypoacetylated through the action of histone deacetylases (HDACs) and methylated on cytosinephosphate-guanine (CpG) dinucleotides by DNA methyltransferases (DNMTs). Acetylation of histones can change the physicochemical properties of these proteins, interfering with the electrostatic attraction between positively charged histones and negatively charged DNA. Furthermore, specific histone tail modifications offer binding sites for the recruitment of other chromatin modification machinery. For example, specific histone tail residue methylation events may be associated with gene activation and others with gene repression (Figure 1 ).
Sequence-specific transcription factors in hematopoiesis
During hematopoiesis, the controlled expression of lineage-specific genes is crucial for proliferation and differentiation cues. Many transcription factors are absolutely essential for the development of a hematopoietic lineage, for example GATA-1 is required for the erythroid and megakaryocytic lineage, while PU.1 is required for myeloid development. The retinoic acid receptor (RAR), which is required for neither lineage clearly plays a modulatory role in the production of blood cells. The ability of such factors to influence cell fate is related to the ability of transcription factors to:
Recognize specific DNA sequences via DNA-binding domain Transcription factors are modular with generally distinct DNA-binding and transcriptional effector domains. A number of DNA-binding domains have been characterized including the homeodomain, zinc-finger domain, leucine zipper domain, winged helix, erythroblast transformation-specific domain (ETS) and helix-loop-helix domains. In the past, the determination of targets of transcription factors was based on a candidate gene approach. With the advent of technologies such as chromatin immunoprecipitation-promoter tiling arrays (ChIP-CHIP) and protein-binding microarrays, the ability to probe transcription factor-binding sites on a comprehensive, genome-wide level is now possible (Mukherjee et al., 2004; Oberley et al., 2004) . These studies now allow the identification of canonical and novel binding motifs within promoter, enhancer and transcribed regions of target genes (O'Geen et al., 2007) . ChIP-CHIP experiments also reveal the presence of transcription-priming mechanisms, which involve preassembly of transcriptional machinery at promoters in preparation for mitogenic stimulation, and binding site selection mechanisms, which reveal that transcription factor binding is not only dependent on sequence recognition but also on chromatin structure that is associated with specific epigenetic marks found in 'euchromatic islands'. For example, transcriptional regulation by Myc involves recognition of E-boxes within the context of trimethylated H3 lysine 4 (H3K4) and H3 acetylation and typically correlates with preassembled RNA Pol II (Guccione et al., 2006) .
Recruit either co-activators or co-repressors to the regulatory regions of genes via protein interaction domains The ability of transcription factors to affect gene transcription is dependent on the specific association of activator or repressor regions of transcription factors with co-activators or repressors. These cofactors may Figure 1 Sequence-specific transcription factors act as docking molecules for the recruitment of DNA and histone-modifying activities to target gene promoters. Active transcription is associated with hyperacetylation and methylation of H3K4, H3K79 and H3K36 residues in promoter regions, whereas gene repression is associated with DNA methylation, hypoacetylation and methylation of H3K9, H3K27 and H4K20 residues. These modifications are mediated by chromatin-modifying enzymes including DNA methyltransferases (DNMTs), histone acetyltransferases (HATs)/histone deacetylases (HDACs), histone methyltransferases (HMTs) and histone demethylases (HDMs).
serve to scaffold basal transcriptional machinery to target genes, recruit chromatin-modifying enzymes (see below) or to covalently modify transcription factors thereby altering activities such as DNA binding, protein-protein interactions, nuclear transport and degradation. For example, the p300/CBP co-activator is recruited by transcription factors to target genes frequently via a specific amino acid sequence known as a KIX domain (Kasper et al., 2002) , where it catalyses acetylation of core histones, correlating with transcriptional activation (Blobel, 2002) , however p300 can also enhance transcriptional repression, as in the case of acetylation of the promyelocytic leukemia zinc-finger protein (PLZF; Guidez et al., 2005) . Transcriptional repressors may interact with co-repressors via conserved domains, such as the BTB/POZ domain found in the PLZF-RARa fusion protein present in patients harboring the t(11;17) translocation. Interaction of PLZFRARa with the nuclear receptor co-repressor (NCoR) and silencing mediator of retinoid and thyroid receptors (SMRT) leads to the recruitment of associated HDACs and transcriptional repression (Melnick et al., 2002) .
Recruit chromatin remodeling machinery
Transcriptional regulation frequently requires the movement of nucleosomes, which can block access to DNAbinding proteins, polymerases and accessory factors to the gene. Remodeling of chromatin and physical displacement of the nucleosome require ATP hydrolysis. Chromatin remodeling machinery includes imitation switch-containing (ISWI) complexes, which mediate nucleosome sliding in vitro (Langst and Becker, 2001) ; the SWI/SNF complexes, containing the Brg or Brm ATPases, which can remove histones from DNA, or transfer them from one DNA strand to the other (Fan et al., 2003) ; and the NuRD multifunctional repression complex (Zhang et al., 1999) .
Respond to hormone through ligand-binding domains For example, the RAR and retinoic acid X receptor (RXR), which are part of a family of hormoneresponsive nuclear receptors including the estrogen, vitamin D 3 , thyroid and steroid hormone receptors, are typically associated with NcoR and SMRT co-repressor molecules in the absence of ligand. Upon treatment with retinoic acid (RA), however, these receptors undergo a conformational change that results in the release of corepressors and binding of co-activators, thus facilitating transcription (Mangelsdorf et al., 1995) . In some instances, the interplay between nuclear hormone receptors and lineage-specific transcription factors may also regulate gene expression. For example, during erythropoiesis, the estrogen receptor has been shown to negatively affect GATA-1-dependent transcription in a ligand-dependent manner, suggesting that members of the steroid receptor family may exert their diverse functions by interfering with cell-specific transcription factors (Blobel et al., 1995) .
The precise regulation of transcription factors and associated machinery is frequently deregulated in malignancy. In hematological malignancies, recurring chromosomal translocations may lead to the formation of novel fusion proteins or overexpression of transcription factors in inappropriate temporal or developmental patterns. As a result, factors and enzymes responsible for catalysing these epigenetic modifications, in particular DNMTs, HATs, HDACs and histone methyltransferases (HMTs) and nucleosome displacement machinery are aberrantly deployed. This may lead to global shifts in gene expression, which frequently lead to increased self-renewal in the malignant cells at the expense of normal differentiation. Elucidating the mechanisms of aberrant epigenetic deregulation in specific hematological malignancies including acute promyelocytic leukemia (APL), lymphoma and myelodysplasia has already led to targeted therapies.
DNA methylation: a mark of stable gene silencing DNA methylation involves the addition of a methyl group at position C5 of the cytidine ring in the context of a CpG dinucleotide, and is catalysed by a family of DNMTs including DNMT1, which preferentially targets hemi-methylated DNA and is required for 'maintenance' methylation during DNA replication; and DNMT3A and DNMT3B which are required for de novo methylation (Okano et al., 1998) . In the mammalian genome, the distribution of CpG dinucleotides, which are predominantly methylated, is statistically underrepresented (B1 CpG per 100 bp), however the dinucleotide frequency occurs at near-expected levels in the promoters of an estimated 60% of human genes (B1 CpG per 10 bp), where cytosines are typically hypomethylated (Antequera and Bird, 1993) . This enrichment of CpG dinucleotides in gene promoters is likely the result of spontaneous deamination of methylated cytosines to thymidine in nonregulatory sequences and these CpG-rich regions are typically referred to as 'CpG islands'.
The regulation of gene expression by DNA methylation of target gene promoters is crucial for the control of several developmental processes including X inactivation (Goto and Monk, 1998) , genomic imprinting (Schaefer et al., 2007) , embryonic Hox gene patterning (Terranova et al., 2006) and hematopoiesis. DNA methylation patterns are perturbed in many human cancers and typically involve regional hypermethylation of CpG islands affecting tumor suppressor genes, for example, p15
INK4b (CDKN2B) and p16 INK4a (CDKN2A), which are silenced in lymphoid and myeloid malignancies that occur within an overall setting of genome-wide DNA hypomethylation, which has been linked to genomic instability (Galm et al., 2006) . The identification of promoter hypermethylation 'signatures' linked to certain epithelial tumors and leukemia subtypes suggests that there is interplay between transcription factors and DNA methylation complexes regulating normal cellular differentiation that are awry in cancer cells (Esteller, 2003; van Doorn et al., 2005; Shames et al., 2006) . DNA methylation of CpG islands is associated with transcriptionally silent chromatin, however whether DNA methylation induces transcriptional silencing per se, or functions as a stabilizer of silencing, remains enigmatic. Although the exact hierarchy of events is unclear, the net effect of DNA methylation is local histone deacetylation and a closed chromatin configuration resulting in gene repression via two mechanisms. First, the presence of methyl groups acts to repel the binding of specific transcription factors, for example, in the case of the murine H19/Igf2 imprinting control region on chromosome 7-69.09cM, which acts as a transcriptional insulator. Specifically, methylation of CpG dinucleotides on the paternal allele blocks binding of CTCF and allows a downstream enhancer to activate Igf2 expression via a looping mechanism (Bell and Felsenfeld, 2000; Yoon et al., 2007) . Second, DNA methylation leads to the recruitment of methyl-CpGbinding domain (MBD) proteins which include five members: MeCP2, MBD1, MBD2, MBD3 and MBD4 (Fatemi and Wade, 2006) . These proteins interact with cytosine methyl groups within the major groove of DNA and through their interactions with DNMTs, specific transcription factors and chromatin-modifying enzymes are capable of repressing gene transcription. For example, MeCP2 has been shown to exist in a complex with the transcriptional co-repressor Sin3A and HDACs (Nan et al., 1998) , and repressed the ability of PU.1 to activate transcription through its cognatebinding site (Bird, 2002; Suzuki et al., 2003) .
The epigenetic control of the human a-and b-globin genes during erythropoiesis is considered a paradigm for differentiation-induced methylation changes during normal hematopoiesis. During erythropoiesis, the maturation of erythrocytes is associated with increased expression of a-and b-globin genes, which is required to synthesize large amounts of hemoglobin (B3 Â 10 8 molecules per cell). The b-globin locus is located on chromosome 11 and consists of five genes e, Gg, Ag, d and b which are under the regulation of a locus control region, located 6-22 kb upstream of the e-globin gene (Levings and Bungert, 2002) . In non-erythroid cells, these genes exist in a methylated, transcriptionally silent state. During erythroid differentiation, however, individual genes within the b-globin locus corresponding to embryonic (e), fetal (GgAg) and adult (d, b) stages of erythropoiesis are expressed in a sequential fashion, such that embryonic/fetal genes are ultimately silenced and adult genes are activated. The reactivation of fetal g-globin in patients with sickle cell disease using the HDAC inhibitor (HDACI) sodium phenylbutyrate (Dover et al., 1992) and the DNMT inhibitor (DNMTI) 5-aza-2 0 -deoxycytidine (5Aza-dC) (Saunthararajah and DeSimone, 2004 ) demonstrated the therapeutic potential of reversing such epigenetic marks, and set the scene for its application in hematological malignancies.
The mechanism of reactivation using 5Aza-dC is related to the depletion of functional DNMTs which become bound in a complex with 5Aza-dC-incorporated DNA, however the ability of 5Aza-dC to selectively degrade DNMT1 has also been reported (Ghoshal et al., 2005) . The use of DNMTIs in combination with HDACIs has also been successfully used to reactivate silenced, hypermethylated tumor suppressor genes in human cancer cell lines. Studies by Cameron et al. (1999) demonstrated that administration of trichostatin A (TSA) following treatment with low doses of 5Aza-dC, synergistically reactivated the expression of MLH1, TIMP3, p15
INK4b and p16 INK4 in tumor cells (Cameron et al., 1999) . Combinatorial treatment of mice with 5Aza-dC and sodium phenylbutyrate was also able to significantly reduce lung tumor development initiated by a tobacco-specific carcinogen in mice (Belinsky et al., 2003) . Since then, clinical trials involving the sequential administration of 5-azacytidine and sodium phenylbutyrate in patients with myelodysplastic syndrome or acute myeloid leukemia (AML) have been conducted. These studies demonstrated an enhanced clinical response rate that was associated with demethylation of p15
INK4b and acetylation of histones H3 and H4 (Gore et al., 2006) . Interestingly, induction of histone acetylation was observed before HDACI was administered, and although the mechanism by which 5Aza-dC results in histone acetylation is unknown, it appears that CpG island methylation is the dominant epigenetic mark responsible for stable gene silencing.
Studies of the globin gene locus have also provided insights into potentially new mechanisms of epigenetic regulation. For example, the initial activation of embryonic/fetal genes is thought to be a result of promoter demethylation, as opposed to de novo methylation in adults, since differentiation of HSCs derived from either baboon fetal liver (FL) and adult bone marrow (ABM) into mature erythroblasts is accompanied by a progressive decrease in g-globin promoter methylation and the concomitant activation of transcription in both FL and ABM (Singh et al., 2007) . These results suggest the existence of a DNA demethylase activity to counterbalance the repression mediated by DNMTs, and would also explain the active demethylation of the paternal genome that is observed shortly after fertilization (Kishigami et al., 2006) . The identification of ROS1 in Arabidopsis, which has DNA glycosylase/lyase activity specific for methylated substrates, and whose mutation is associated with DNA hypermethylation and gene silencing, provides evidence for such an activity (Kapoor et al., 2005) . Alternatively, demethylation may occur with replication of DNA during differentiation and failure to remethylate daughter strands. The significance of a DNA demethylase, however, and other as yet undiscovered epigenetic marks/modifying proteins, lies in the ability to target the aberrant forms of these activities in a more specific manner.
Similar to the globin locus, the expression of specific transcription factors required for the differentiation of other hematopoietic lineages is regulated by promoter methylation, and as such, these genes also represent potential targets for disruption in hematological malignancies. For example, PU.1 (SPI1) is highly expressed in HSCs and differentiated B cells, but not in T cells, correlating with the methylation status of the PU.1 5 0 UTR, which is hypermethylated in CD4 þ and CD8 þ cells (Ivascu et al., 2007) . PU.1 overexpression has been linked to peripheral T-cell lymphoma (Mahadevan et al., 2005) , and mice with deletion of a regulatory element upstream of PU.1 developed AML (Rosenbauer et al., 2006; Ivascu et al., 2007) . Furthermore, hypomethylation of PU.1 was observed in patients with diffuse large B-cell lymphoma compared to normal lymph nodes, highlighting the requirement for tight epigenetic control of PU.1 in normal hematopoiesis (Ivascu et al., 2007) . Differential methylation of regulatory elements controlling the expression of other lineage-determining transcription factors has also been observed, including GATA3, which displays reduced methylation in naive and memory CD4 þ cells compared to CD34 þ , CD8 þ , T and B cells, correlating with its known role in maturation of single-positive CD4 cells. As another example, TCF7 and Etv5 display higher methylation in B and T memory cells compared to naive counterparts (Ivascu et al., 2007) . The provenance of the aberrant methylation of specific target genes in the cancer cell remains to be fully elucidated. One source may be the aberrant expression of DNMTs normally responsible for the restricted wave of methylation during blood development. Indeed the overexpression of DNMT1 and 3B, in addition to members of the methyl-CpG-binding proteins, has been reported in numerous malignancies including ovarian (Ahluwalia et al., 2001) , breast (Butcher and Rodenhiser, 2007) , prostate (Patra et al., 2002) and lung cancers (Lin et al., 2007) . Furthermore, studies by Ostler et al. (2007) reveal that truncated DNMT3B proteins deficient in the C-terminal catalytic domain are expressed in numerous cancer cell lines and primary acute leukemias. Overexpression of the most frequently expressed aberrant transcript, DNMT3B7 in 293 cells, led to alterations in gene-expression patterns which corresponded with DNA methylation at CpG islands of these promoters, further supporting the role of DNMTs in the abnormal patterns of methylation observed in cancer cells (Ostler et al., 2007) . Aberrant gene methylation in leukemia may also arise by the recruitment of DNMTs and associated chromatinmodifying proteins by cell type-specific transcription factors, which are commonly dysregulated in hematological malignancies including PML-RARa (Di Croce et al., 2002) and RUNX1/MTG8 (Liu et al., 2005) . The identification of such complexes and their specific target genes is likely to provide important insights into methylation-induced silencing in leukemic cells.
Histone acetyltransferases and histone deacetylases: roles in normal hematopoiesis and leukemia
The acetylation of core histone tails in relation to gene expression has been extensively studied and is regulated by the opposing activities of HATs, which catalyse the transfer of acetyl groups from acetyl-CoA to lysine residues of target proteins, and HDACs, which catalyse the removal of acetyl groups. The ability of histone acetylation to regulate gene expression occurs via the direct effect of this modification on higher order chromatin structure, which serves to neutralize the charge between histone tails and the DNA backbone, and also by serving as a docking site for bromodomaincontaining regulatory factors. In general, hyperacetylation of histones is associated with structurally 'open' chromatin and gene transcription, whereas histone deacetylation is linked to gene repression and/or heterochromatin formation (Verdone et al., 2006) . HATs can be divided into three groups on the basis of their catalytic domains and comprise GNATs (Gcn5 N-acetyltransferases) which include Gcn5, p300/CBPassociated factor (PCAF), Elp3, Hat1, Hpa2 and Nut1 members; MYSTs, which include MOZ, MORF, Ybf2/ Sas3, Sas2, HBO1 and Tip60 members; and p300/CBP (cAMP response element-binding (CREB) protein) (Lee and Workman, 2007) . These enzymes are recruited to target promoters by cell-specific transcription factors or chromatin-binding subunits such as bromodomaincontaining proteins, or may even directly bind DNA, as in the case of activating transcription factor-2 (Kawasaki et al., 2000) . HDACs can also be divided into categories on the basis of sequence and domain similarity, and include Class I HDACs (HDAC1-3 and HDAC8), which possess homology to yeast Rpd3 and are localized to the nucleus; Class II HDACs (HDAC4-7, HDAC9 and 10), which display similarity to the deacetylase domain of yeast Hda1 and travel between the nucleus and the cytoplasm; Class III HDACs, which consist of the silent information regulator (SIR2) family of nicotinamide adenine dinucleotide-dependent deacetylases (SIRT1-8) and Class IV HDACs (HDAC11) (Minucci and Pelicci, 2006; Ouaissi and Ouaissi, 2006) . Like HATs, HDACs function within the context of a multiprotein complex that includes DNA-binding transcriptional factors/unliganded nuclear receptors and co-repressor proteins such as NcoR, SMRT, Sin3a and NURD (Cress and Seto, 2000) .
In addition to regulating transcription by affecting chromatin structure, HATs and HDACs are also capable of indirectly affecting gene expression by modifying non-histone substrates (Minucci and Pelicci, 2006) . The acetylation of specific lysine residues of transcription factors has been shown to affect the subcellular localization, DNA binding, transcriptional activity, protein-protein interactions and stability of several key transcription factors including p53, STAT3, RUNX1 and ETS, and not surprisingly, alterations in HAT/HDAC activity are linked to multiple cancers (Bruserud et al., 2006) .
During hematopoiesis, lineage-restricted transcription factors regulate specific gene-expression patterns by recruiting HAT or HDAC complexes to the promoters of target genes (Huo and Zhang, 2005) . For example, during erythropoiesis, erythroid-specific transcription factors including GATA-1, which is essential for red blood cell maturation and survival, directly recruit HAT-containing complexes to the b-globin locus to stimulate transcriptional activation. Specifically, GATA-1 recruits CBP to the b-globin gene locus, resulting in the acetylation of histones H3 and H4, and facilitating high-globin gene expression (Letting et al., 2003) . GATA-1 itself is also acetylated on conserved lysine residues by CBP, and although the effect of this modification remains controversial, the net result is enhanced transcriptional activity (Boyes et al., 1998; Hung et al., 1999) .
In leukemia, the ectopic expression of wild-type (for example, TAL1/stem cell leukemia (SCL), BCL6) or chimeric transcription factors (for example, RUNX1-MTG8, TEL-AML1, PML-RARa and PLZF-RARa) results in the aberrant recruitment of histone-modifying activities to target genes that play important roles in cell cycle control and differentiation. TAL1/SCL, first identified by its translocation in T-cell acute lymphoblastic leukemia (T-ALL) (Begley et al., 1989 ) is a member of the basic helix-loop-helix (bHLH) transcription factors. TAL1/SCL is essential for the development of erythroid and megakaryocytic lineages, while negatively affecting myeloid differentiation. TAL1/SCL binds E-box motifs as a heterodimer with other bHLH proteins including E12, E47, HEB and E2-2, and is capable of activating and repressing transcription depending on the specific association with co-activator or co-repressor complexes. For example, acetylation of TAL1/SCL by the co-activators p300 and the PCAF is linked to increased transcriptional activation and differentiation of murine erythroleukemia (MEL) cells in culture (Huang et al., 1999 , while the association with a co-repressor complex including mSin3A and HDAC1 in MEL and human T-ALL cells was linked to transcriptional repression and inhibition of erythroid differentiation . The association between TAL1/SCL and mSin3A/ HDAC1 declined upon MEL differentiation, suggesting that mSin3A and HDAC1 may inhibit the ability of TAL1/SCL to potentiate erythropoiesis and highlighting a possible mechanism for SCL-induced leukemogenesis . Indeed, overexpression of Tal1/Scl in an E2A or HEB heterozygous background induced thymocyte differentiation arrest that was linked to the depletion of E47/HEB heterodimer and recruitment mSin3A/HDAC1 to the CD4 enhancer (O'Neil et al., 2004) . These tumors were hypersensitive to HDAC inhibitors, consistent with the notion that leukemogenesis by ectopically expressed TAL1/SCL was mediated by aberrant gene repression due to recruitment of co-repressor complexes.
Translocations affecting HATs have also been implicated in tumorigenesis. For example, the rare translocations t(8;16)(p11;p13) and t(10;16)(q22;p13) fuse the MOZ (MYST3) and the MORF HATs with CBP in AML (Panagopoulos et al., 2001; Rozman et al., 2004) . In the case of the t(10;16)(q22;p13) translocation, the generation of MORF-CBP, which harbors the zincfingers, nuclear localization signals (NLS) and HAT domain of MORF, and the RARa-binding domain, CREB-binding domain, bromodomain and HAT domain of CBP, is thought to promote aberrant patterns of acetylation; however since both reciprocal fusion proteins are expressed, the leukemogenic potential of these fusion proteins is unclear. Irrespective of the exact mechanism, the expression of these fusion proteins is associated with the loss of monoacetylated H4K16, which was recently identified as a common mark of cancer transformation (Fraga and Esteller, 2005) . The mixed lineage leukemia (MLL) gene is also involved in a translocation involving CBP, and the resultant MLL-CBP fusion has been shown to require both the CBP bromodomain and HAT domain for leukemic transformation (Santillan et al., 2006) . These findings highlight the importance of HATs and HDACs in regulating genome-wide and loci-specific chromatin structure.
Histone methyltransferases: roles in normal hematopoiesis and leukemia
The methylation of histones on lysine and arginine residues by HMTs represents another level of gene regulation, and is probably the most complex of the epigenetic modifications: arginines can be monomethylated or dimethylated (symmetrically or asymmetrically); lysines can be mono-, di-or trimethylated. While arginine methylation is usually associated with gene activation, lysine methylation can be related to transcriptional activation as well as repression depending on the residue modified. For example, methylation of histone H3K4, H3K36 and H3K79 is associated with transcriptional activation, whereas H3K9, H3K27 and H4K20 methylation is usually linked to gene repression (Shilatifard, 2006) . It is becoming increasingly obvious that the association between the modification of a certain residue and its effect on transcription is not so simple, however, especially in light of recent evidence demonstrating that the processivity (mono-, di-or tri) and spatial context of lysine methylation across a given locus determines the net effect on gene expression. This can be demonstrated in the case of H3K9, which is typically associated with heterochromatin and gene repression. For example, a recent study of the histone methylation patterns in a highly active transcribed gene, poly(A)-binding protein C1, revealed increased levels of H3K9Ac at the expense of H3K9me3 in the transcriptional start site ( þ 0.5-5 kb); however, high levels of H3K9me3 were identified across the entire transcribed region (Vakoc et al., 2006) . The functional significance of such coding region methylation may be related to the requirement for recondensation of chromatin following transcription elongation-associated acetylation. For example, Carrozza et al. (2005) demonstrated that the deposition of H3K36 methyl marks across the coding region of active genes, such as STE11, acts as a marker for HDAC complexes that restore chromatin configuration following RNA polymerase activity, thus suppressing erroneous transcription from cryptic promoters.
Histone methyltransferases can be classified into three main groups, and catalyse the transfer of a methyl group from the methyl donor S-adenosylmethionine (SAM) to the e-nitrogen in lysine or the guanidinium nitrogen in arginine. These include (1) lysine-specific SET-containing HMTs involved in the methylation of H3K4, H3K9, H3K27, H3K36 and H4K20 residues; (2) non-SET HMTs involved in H3K79 methylation and (3) protein arginine methyltransferases (PRMTs) that specifically methylate H3R2, H3R17, H3R26 and H4R3. The SET domain, which is an acronym for three prototypical chromatin regulators in the fly, Su(var)3-9, enhancer of zeste and trithorax, is a 130-140 amino acid motif found in a number of chromatin-modifying proteins. SETcontaining proteins from Drosophila (Rea et al., 2000) , yeast (Nakamura et al., 2002) and human (Rea et al., 2000) have HMT activity that maps to the SET domain and in some of these proteins, cysteine-rich sequences flanking the domain were also required for methyltransferase activity. The molecular basis for the specificity of particular SET proteins for specific histone residues is not yet understood but is being approached by structural biology studies of the SET domain in complex with its substrates (Trievel et al., 2002) . The structure of SET domains was solved by a number of laboratories, and based upon these structures two critical regions were identified; one that binds the methyl donor SAM and the other that binds histones and lysine residues. Modification of SET proteins in vitro can lead to changes in the ability of an enzyme to singly or multiply methylate a specific lysine residue (Zhang et al., 2003; Qian and Zhou, 2006) . Mutations that affect which lysine residue is specifically modified, however, have not yet been identified. The future identification of such a residue that can alter SET domain specificity could lead to the production of designer HMTs that could be deployed to modify chromatin in a controlled, artificial manner as well as the design of more specific HMTs inhibitors.
These HMTs form large, multiprotein complexes that typically contain other histone modifier enzymes, such as HATs, HDACs, DNMTs and histone demethylases (HDMs). HMTs may be co-activators or co-repressors of transcription factors that recruit complex epigenetic machinery to specific target promoters involved in critical processes, such as proliferation and differentiation. The important role of these enzymes during hematopoiesis is underscored by the finding that the overexpression or dysregulation of HMTs is found in multiple hematopoietic malignancies (Table 1) .
Histone lysine (K) methyltransferases
Histone lysine (K) methyltransferases (HKMTs) are important regulators of normal hematopoiesis and have been shown to regulate lineage commitment decisions in concert with cell-specific transcription factors. In Drosophila, the activation and repression of developmentally regulated loci is maintained by trithorax group (trxG) and polycomb group (PcG) proteins, respectively, and since then mammalian homologs of these genes have been identified where they have been shown to maintain patterns of Hox gene expression during embryogenesis. The MLL protein, which resembles trx, belongs to the SET1 family of HMTs (including SET1A, SET1B and four MLL HMTs) that specifically methylates H3K4, a mark typically associated with gene activation. MLL plays a critical role in the proliferation and lineage-determination of hematopoietic progenitors during embryonic development, by maintaining the expression of HOX genes, such as Hoxa7 and Hoxa9 (Ernst et al., 2002 (Ernst et al., , 2004 . Like many transcriptional regulators, MLL is bi-functional, balancing both transcriptional repression and activation roles: it represses target genes through the recruitment of PcG proteins, HDACs and/or SUV39H1 (Xia et al., 2003) , and activates genes through its H3K4 methyltransferase activity and by recruitment of HATs such as MOF and CBP (Ernst et al., 2001; Milne et al., 2002; Dou et al., 2005) . The role of MLL during normal hematopoiesis is underscored by the finding that chromosomal translocations involving the MLL gene on chromosome 11q23 and more than 60 different fusion partners occur in a significant proportion of patients with AML and ALL (Daser and Rabbitts, 2005) . Furthermore, an internal tandem duplication of MLL is one of the commonest genetic anomalies in AML with a grossly normal karyotype. Although the MLL fusion proteins generally lack their own SET domain, as well as the CBP-binding domain, the DNAbinding domain is retained in the MLL fusion protein, and the upregulation of MLL target genes such as Hoxa9 and Hoxa7, which have leukemogenic potential, is thought to account for the oncogenic properties of MLL-X fusions (Kroon et al., 1998; Ayton and Cleary, 2003) .
The PcG proteins counterbalance this positive regulation of homeotic genes (in addition to silencing genes during processes such as X-inactivation and genomic imprinting) by acting as negative regulators of transcription. PcG proteins play essential roles in embryonic development and stem cell renewal and as such represent targets for deregulation in leukemia. PcG proteins function in the context of biochemically distinct, multiprotein complexes known as polycomb repressive complexes (PRC), and in mammals, these complexes include the PRC1 complex, which contains PcG, RING domain proteins, and BMI1 (B cell-specific moloney murine leukemia virus integration site 1), as well as PRC2, 3 and 4, comprised of enhancer of zeste protein-2 (EZH2), which specifically methylates H3K27 and H1K26 in a complex-dependent manner, SUZ12, histone-binding proteins RbAp46 and 48 and one of four forms of embryonic ectoderm development (EED). Upon recruitment of PRCs to specific loci, transcriptional repression is thought to occur following the trimethylation of H3K27 by PRC2 or PRC3, which serves as a marker for PRC1 binding (Squazzo et al., 2006) . PRC1-binding blocks the activating function of the ATP-dependent remodeling enzyme, SWI/SNF, thereby facilitating a repressive chromatin environment (de la Serna et al., 2006) . In addition, PRC1 also recruits RING domain proteins, which are implicated in the ubiquitylation of H2A-K119, and BMI1, a protein that activates RING protein activity, to target loci. Although the exact role of ubiquitylation in relation to gene silencing is unclear, this modification has been shown to be required for Hox gene silencing (Cao et al., 2005) .
EZH2 overexpression is associated with increased cell growth and is common in prostate cancers and lymphoma. Mice deficient in EZH2 showed impaired B-cell development and decreased rearrangement of the immunoglobulin heavy chain (Su et al., 2003) . Since EZH2 requires the presence of the other PRC2, 3 and 4 members for HMT activity, it is not surprising that dysregulation of other PRC components may also be linked to tumorigenesis. Indeed, downregulation of the polycomb component EED is associated with an increase incidence of carcinogen-induced lymphoma (Richie et al., 2002) . Similarly, dysregulation of BMI1 also affects the activity of the PRCs, and overexpression and overactivity of BMI1 has been associated with a variety of solid tumors including lung, breast, colon, prostate and neuroblastoma as well as in malignant hematopoiesis (Breuer et al., 2004; Glinsky et al., 2005; Steele et al., 2006) . Given its critical role in normal stem cell function, it seems likely that BMI1 plays an important role in the ability of the cancer cell to undergo limitless self-renewal (Lessard and Sauvageau, 2003) .
SUV39H1 and SUV39H2 are homologs of the Drosophila Su(var)3-9 (suppressor of position-effect variegation) HMTase, and were originally shown to be crucial for the formation of heterochromatin by selective trimethylation of H3K9 (Aagaard et al., 1999) . This methyl mark is recognized by the chromodomain of heterochromatin protein 1 (HP1), which recruits additional HP1 molecules and other chromatin-modifying proteins, thereby spreading and maintaining the heterochromatin state. Since then, the involvement of SUV39H1 an SUV39H2 in regulating hematopoietic-specific gene transcription has been clearly demonstrated. For example, during the differentiation of myeloid and erythroid lineages from common progenitors, PU.1 recruits SUV39H1, HP1 and the retinoblastoma (Rb) proteins and binds to GATA-1 on its target genes, thereby inhibiting erythroid differentiation (Stopka et al., 2005) . The interaction of SUV39H1 and HP1 with Rb also implicates these chromatin modifiers in cell cycle regulation and cellular senescence by repressing genes such as Cyclin A, Cyclin E and E2F, and as such, SUV39H1 may function as a tumor suppressor (Ait-Si-Ali et al., 2004). Indeed, loss of Suv39h1 has been shown to induce dramatic genome instability, associated with loss of H3K9 methylation, and increases the development of B-cell lymphomas (Peters et al., 2001 ) and T-cell lymphomas in mice (Braig et al., 2005) . RUNX1, which plays an essential role in myelopoiesis and is responsible for the silencing of CD4 during T-cell maturation, has also been shown to interact with SUV39H1. Studies by Reed-Inderbitzin et al. (2006) demonstrated recruitment of Suv39h1 by Runx1 to an oligonucleotide containing the band 3 upstream regulatory element, which has been shown to mediate RUNX-1-dependent repression in MEL cells, suggesting that RUNX1 may repress a subset of target genes by modifying H3K9. RUNX1 function is disrupted through the t(8;21) translocation present in 10-15% of myeloid leukemias, which fuses the N-terminal portion of RUNX1 to MTG8, leading to the recruitment of HDACs and aberrant silencing of RUNX1 target genes. Given that the interaction of RUNX1 and SUV39H1 involves domains retained in the t(8;21) fusion proteins, this suggests that SUV39H1, in addition to HDACs and DNMTs may be involved in the The symbols (+) activation or (À) repression refer to the effect of the modification on transcription (me1, 2, 3 refer to mono-, di-or trimethylation).
repression of genes contributing to leukemic transformation (Liu et al., 2005; Reed-Inderbitzin et al., 2006) . G9a is the major H3K9 mono-and dimethyltransferase in euchromatin and can also modify the methylation status of H3K27, by functioning as heterodimer with G9a-like protein (GLP)/EHMT1 . Similar to SUV39H1, G9a-mediated repression is initiated by H3K9 methylation, followed by recruitment of HP1 and DNMT1, and culminating in CpG island methylation. HP1 enhances DNMT1 activity, while DNMT1 stabilizes the binding of HP1 to ensure stable gene silencing (Smallwood et al., 2007) . This idea is supported by the finding that siRNAmediated knockdown of G9a is associated with DNA hypomethylation (Ikegami et al., 2007) . Intriguingly, GLP/EHMT1 was recently identified as a gene mutated in breast cancer, with at least one mutation mapping to the active site of the protein, potentially eliminating HMT activity (Cebrian et al., 2006) . The functional consequences of these mutations on G9a/GLP function are yet to be determined, however this finding and the sheer number of SET domain containing HMTs in the genome (B60) suggest that these enzymes might be more commonly affected in malignancy.
Consistent with this idea, another HMT that methylates the H3K9 histone tail residue is RIZ1 (PRDM2). This tumor suppressor protein is inactivated in many human cancers by deletion, frameshift mutations, promoter hypermethylation and missense mutations (Canote et al., 2002) . Many cancer-associated mutations in RIZ affect its HMT activity, suggesting an important role for this activity in suppression of tumor formation (Kim et al., 2003) . RIZ1 knockout mice develop B-cell lymphoma (Steele-Perkins et al., 2001) , and in chronic myelogenous leukemia (CML), blastic transformation is associated with loss of heterozygosity in the vicinity of RIZ1 and a decrease in RIZ1 expression (Pastural et al., 2007) . Overexpression of RIZ1 in a model CML blast crisis cell line also reduced cellular proliferation and enhanced differentiation, confirming a potential tumor suppressor role mediated by RIZ1.
The NSD family of SET domains includes NSD1, MMSET (NSD2) and NSD3 (Stec et al., 1998) . NSD1, which methylates H3K36 and H4K20 residues, is implicated in AML as a result of the t(5;11) translocation that fuses NSD1 to NUP98, a subunit of the nuclear pore complex that is frequently rearranged in leukemia (Jaju et al., 2001) . In humans, mutation of NSD1 is associated with familial gigantism (van Haelst et al., 2005) , as well as with Sotos syndrome, which is characterized by fetal overgrowth, malformations and increased risk of leukemia, suggesting that NSD1 might function as a tumor suppressor (Kurotaki et al., 2002; Douglas et al., 2005) . MMSET (NSD2) was identified at the breakpoint of the t(4;14) translocation present in B15% of multiple myelomas, which results in the overexpression of both FGFR3 and MMSET (Chesi et al., 1998; Stec et al., 1998) . Preliminary data from our laboratory suggest that MMSET specifically methylates H4K20 (Licht, unpublished data), and given the presence of functional domains including NLS, a high mobility group box, in some proteins a DNA-binding motif, two proline-tryptophan-tryptophan-proline domains which are critical for chromatin targeting (Stec et al., 1998 (Stec et al., , 2000 Chen et al., 2004; Ge et al., 2004) and four plant homeodomain zinc-fingers, often involved in protein-protein interactions (Aasland et al., 1995) suggest that MMSET is a transcriptional regulator. NSD3 is located in a genomic region amplified in breast cancer (Angrand et al., 2001) and is also fused to NUP98 in AML associated with the t(8;11) translocation (Rosati et al., 2002) .
hDOT1L is an HMTase that lacks the SET domain and specifically methylates H3K79, a residue located within the globular domain of histone H3, rather than the histone tail. Intriguingly, hDOT1L has been shown to interact with AF10, one of several fusion partners of MLL involved in the pathogenesis of leukemia. The direct fusion of MLL and hDOT1L resulted in immortalization of murine myeloid progenitors and was associated with the upregulation of several genes implicated in leukemogenesis including Hoxa7, Hoxa9 and Meis1 (Okada et al., 2005) . This activity was associated with an increased H3K79 methylation on Hoxa9 genes in cells transduced by MLL-hDOT1L, suggesting that the ability of MLL to recruit hDOT1L to target promoters may be a critical mechanism of leukemogenesis. Recently, hDOT1L has also been associated with leukemic transformation mediated by the Clathrin-assembly protein-like lymphoid-myeloid-AF10 (CALM-AF10) fusion protein identified in patients with T-ALL and AML (Okada et al., 2006) . The association of hDOT1 with CALM-AF10 results in upregulation of Hoxa5 via H3K79 methylation, and also contributes to CALM-AF10-mediated leukemic transformation by preventing nuclear export of CALM-AF10.
Given the frequent involvement of HMTs in cancer, aberrant histone methylation and HMTs themselves represent important potential therapeutic targets. An inhibitor specific for G9a activity, BIX-01294 (diazepinquinazolin-amine derivative) has recently been identified, and has been shown to specifically inhibit H3K9 dimethylation in the promoters of G9a target genes (Kubicek et al., 2007) . Given that G9a-mediated methylation in euchromatin is a mark for HP1 and DNMT1 recruitment, it follows that inhibiting one of the steps in the complicated cascade of event that lead to gene repression could lead to the reactivation of important tumor suppressor genes. Treatment with the DNMTI 5Aza-dC has also been successful in the reactivation of tumor suppressor genes, and recent studies show that this drug also functions by decreasing H3K9 dimethylation in the promoters of breast cancerassociated TSGs, DSC3 and MASPIN (Wozniak et al., 2007) . This decrease is associated with a post-transcriptional decrease in G9a, and represents a novel inhibitory mechanism for the DNMTs inhibitors. Recently, the targeting of PRC2 components EZH2, SUZ12 and EED by the SAM hydrolase inhibitor, DZNep (3-deazaneplanocin A) has also shown promise as a new HMTasetargeted therapy. Treatment of breast cancer cells with DZNep resulted in the reactivation of a number of genes repressed by PRC2 and induced apoptosis in cancer cells but not in normal cells (Tan et al., 2007) .
Protein arginine methyltransferases
The methylation of protein arginine residues has been implicated in numerous biological processes including regulation of transcription, cell signaling, RNA processing, subcellular transport and DNA repair (Pahlich et al., 2006) . PRMTs can be separated into two classes; Type I enzymes catalyse the formation of asymmetric NG,NG-dimethylarginine residues and include PRMT1, PRMT3, PRMT4/CARM1 and PRMT6, whereas Type II enzymes catalyse the formation of symmetric NG,N 0 G-dimethylarginine residues and include PRMT5. Of these, only three PRMTs have been reported to catalyse histone methylation: PRMT4/CARM1 methylates H3R2, R17 and R26; PRMT1 methylates H4R3 and PRMT5 methylates H3R8 and H4R3. Formation of asymmetric dimethylarginine residues in histones by PRMT1 and CARM1 is associated with gene activation, while formation of symmetric dimethylarginine residues by PRMT5 is implicated in gene repression. In addition to affecting chromatin structure by histone methylation directly, PRMTs can also modify proteins with known roles in epigenetic regulation. For example, CARM1 has been shown to methylate the HAT CBP, which negatively affects the co-activator function of CBP/ p300 (Chevillard-Briet et al., 2002) , and recent studies demonstrate that the methyl-DNA-binding domain protein 2 (MBD2), which has been implicated in the formation of colon tumors, is also negatively regulated by arginine methylation (Tan and Nakielny, 2006) .
The role of PRMTs in hematopoiesis, specifically in myeloid differentiation, was highlighted by Balint et al. (2005a, b) , who demonstrated the methylation of H4R3 'primes', the regulatory region of specific genes for RAinduced myeloid differentiation (Balint et al., 2005b) . Treatment of HL60 myeloid leukemia cells with vitamin D or dimethyl sulfoxide induced a 'precommitment' state that was linked to a rapid decrease in promoter H3K4 methylation and an increase in enhancer H4R3 methylation of the tissue transglutaminase gene, whose expression is linked to RA-induced differentiation. These 'primed' cells were then treated with RA, resulting in H4 acetylation and H3K4 methylation and transcriptional activation (Balint et al., 2005b) . Also implicated in this chain of events is the enzyme peptidyl arginine deiminase, PAD4, which removes the methyl mark on H4R3, and is also associated with RA-induced gene activation . Given that methylation of H4R3 has been shown to be a substrate for HATs, these findings fit a model in which PRMT1-specific H4R3 methylation serves as a priming mark for gene activation, which upon exposure to appropriate stimuli (RA) leads to the recruitment of PAD4 and HATs and transcription of genes required for myeloid differentiation. These studies open the possibility of treating diseases resulting from the aberrant activity of PRMTs and a number of histone arginine methyltransferases inhibitors have recently been synthesized (Spannhoff et al., 2007) .
Histone demethylases: the reversibility of stable epigenetic marks Until recently, histone methylation was considered an irreversible epigenetic mark and loss of methylation was explained by histone replacement during replication or by the degradation of histone tails (Allis et al., 1980; Ahmad and Henikoff, 2002) . The recent discovery of two families of HDMs, the amine oxidase enzyme LSD1 and the Jumonji C (JmjC) domain-containing family, however, suggests that regulation of gene expression and chromatin structure by histone methylation is more dynamic than previously thought. Shi et al. (2004) discovered the first histone lysine demethylase (LSD1). This enzyme catalyses lysine demethylation in a flavin adenine dinucleotide-dependent manner and permits the specific removal of monoor dimethylated lysine residues from H3K4 and H3K9 residues. LSD1 has been purified in several different complexes and depending on the association with specific factors, may have a dual role in transcriptional regulation. For example, demethylation of H3K4me1 and H3K4me2 by LSD1 in promoter regions is associated with gene repression and LSD1 has since been identified as part of a repressive multi-subunit complex containing ZNF217, CoREST, HDAC2 and CtBP1, which is capable of repressing the E cadherin promoter (Cowger et al., 2007) . It was proposed that following the deacetylation of the histones by HDACs, LSD1 removes the methyl groups in H3K4, facilitating gene repression (Forneris et al., 2006) . This dependence of LSD1-mediated demethylation on HDAC activity is supported by the negative effect that HDAC inhibitors have on LSD1 activity (Lee et al., 2006) . In contrast, association of LSD1 with the estrogen or androgen receptors leads to demethylation of H3K9me1 and H3K9me2, corresponding to an activation function (Metzger et al., 2005; Garcia-Bassets et al., 2007) . In the context of hematopoiesis, LSD1 has also been identified as a component of a transcription activation complex containing MLL1, and although the functional significance of this interaction is not clear, the dysregulation of MLL in AML suggests that LSD1 may also have links to leukemogenesis (Nakamura et al., 2002) .
The second family of HDMs includes the JmjC enzymes, which catalyse the removal of mono-, di-and trimethyl lysines in the presence of Fe(II) and aketoglutarate. Several JmjC domain proteins have been identified with different specificities including JHDM1 (H3K36me1/2), JHDM2 (H3K9me1/2), JMJD2 (H3K9me2/3, H3K36me3) and JARID1 (H3K4me2/3) ( Table 2) . A recent study by demonstrated the interaction of the JmjC HDM JARID1d with the polycomb-like protein RING6a/ MBLR and showed that RING6a/MBLR enhanced JARD1d-mediated H3K4 demethylation, associated with transcriptional repression. Jhdm1b has also been shown to interact with PcG proteins in a complex containing Ring1b/Rnf2 and the Bcl6 interacting corepressor, among other proteins (Sanchez et al., 2007) . This co-repressor complex may be implicated in gene repression mediated by Bcl6, a transcription factor frequently dysregulated in B-cell lymphomas, and could provide the basis for studying the effect of HDM inhibitors in this disease. JMJD2A has been also implicated in transcriptional repression of E2F-responsive promoters via interactions with the retinoblastoma protein, HDACs and NCoR, suggesting a role for JMJD2A in cell cycle control (Gray et al., 2005) .
Although our understanding of HDMs is fragmentary, the possibility that these enzymes are deregulated in leukemias and other cancers makes them attractive targets for inhibition. Indeed, LSD1, which has been shown to be a co-activator for the androgen receptor by removing H3K9 methylation in a ligand-dependent manner, is a marker for high-risk relapse prostate cancer (Kahl et al., 2006) . Given that LSD1 is similar in structure to monoamine oxidases (MAOs), it is not surprising that MAO inhibitors have a negative effect on LSD1 activity. Recent studies revealed that MAO inhibitors including pargyline and the clinically used antidepressant Parnate are capable of inhibiting LSD1, and provide the basis for developing inhibitors with greater specificity and potency (Yang et al., 2006 . Polyamine analogs have also been shown to be potent inhibitors of LSD1 and were capable of inhibiting LSD1 in human colon carcinoma cells, resulting in the reactivation of aberrantly silenced genes (Huang et al., 2007) .
Patterns of histone modification may be globally altered in cancer
The analysis of global patterns of histone modifications using a combination of ChIP and genomic tiling arrays, high-performance capillary electrophoresis and liquid chromatography-electrospray mass spectrometry, has provided intriguing insights into the structure of the epigenome that characterizes normal and malignant cells (Fraga and Esteller, 2005; Bernstein et al., 2007) . A comprehensive screen of histone H4 modifications in human cancer cell lines and primary tumors compared to normal tissue counterparts revealed an overall loss of both H4K16 monoacetylation and H4K20 trimethylation at repetitive DNA sequences, coinciding with the global loss of DNA methylation typically observed in tumor cells . Given that trimethylation of H4K20 is an important marker for repression of heterochromatin domains, it is postulated that loss of H4K20me3, in conjunction with DNA hypomethylation, contributes to genomic instability frequently observed in tumor cells. The finding that H4K20 methylation also plays a role in DNA damage response in yeast cells provides another mechanism by which loss of methylation may aberrantly affect normal cell cycle checkpoints (Sanders et al., 2004) . It is likely that specific genes are also affected by the loss of H4K20 methylation and H4K16 acetylation. For example, acetylation of H4K16 is associated with active transcription of HOXA9, which is typically dysregulated in myeloid leukemias (Dou et al., 2005) .
Epigenetic regulation by noncoding RNAs
The identification of microRNAs (miRNAs), small interfering RNAs (siRNAs) and Piwi-interacting RNAs (piRNAs) provides yet another mechanism of gene regulation, and recent studies demonstrate that these small regulatory RNAs are capable of regulating gene expression at the transcriptional, post-transcriptional and epigenetic levels (Ambros and Chen, 2007) . Studies in Schizosaccharomyces pombe reveal that an RNAiinduced transcriptional silencing complex (RITS) which contains the siRNAs from the dg and dh repeats at heterochromatic loci, in addition to Chp1, Ago1 and Tas3 proteins, recruits an RNA-directed RNA polymerase complex (RDRC) that in association with other chromatin-modifying proteins is required for heterochromatin assembly at target loci (Verdel et al., 2004) . It is postulated that siRNAs mediate the recruitment of Clr4 (the homolog of Drosophila SU(VAR)3-9) to target loci and that subsequent H3K9 methylation serves as a marker for the RITS complex (via the Chp1 chromodomain protein) and the recruitment of RDRC. The generation of additional siRNAs by the RDRC complex is thought to generate a feed-forward loop that facilitates heterochromatin assembly (Grewal and Elgin, The specific lysine residues targeted and the effect on transcription is outlined.
Epigenetic regulation of hematopoiesis KL Rice et al 2007). Indeed, deletion of several components of this pathway in S. pombe resulted in the loss of H3K9 methylation and expression of integrated transgenes at centromeric heterochromatin (Volpe et al., 2002) . The significance of these findings lies in the fact that many of the proteins involved in heterochromatin formation in S. pombe are conserved in mammals, suggesting the existence of small RNA-induced epigenetic silencing in mammalian cells. The recent finding that Piwi, an Argonaute protein that has been shown to associate with a new class of small RNAs known as piRNAs (Aravin et al., 2006) , interacts with HP1 suggests that these piRNAs may also play a role in heterochromatin formation (Ambros and Chen, 2007) . In animals, small regulatory RNAs in the form of miRNAs are transcribed by RNA polymerase II and are subsequently processed in the nucleus by RNase III Drosha and DGCR8 to yield a 70-100 nt stem loop structure (precursor-miRNA; pre-miRNA). These premiRNAs are exported to the cytoplasm by Exportin-5, and are digested by a complex including a second RNase III, Dicer, in addition to TRBP and AGO2, to yield a 17-25 nt mature miRNA. The mature miRNA is then incorporated in a miRNA-associated RNA-induced silencing complex, where it leads to either the degradation of target mRNAs, in the case of perfect target complementarity, or translational repression via imperfect target binding, typically in the 3 0 UTR of the mRNA transcript. An evidence that miRNAs can also alter the epigenetic status of the cell comes from studies in Arabidopsis, which revealed that mutations altering miRNA-binding sites in the PHABULOSA (PHB) mRNAs affects not only transcript accumulation, but also the methylation status of the PHB gene (Bao et al., 2004) .
RARa translocations in APL: PML-RARa as a model for the interplay between genetic and epigenetic events culminating in leukemia
The molecular biology of APL has represented the leading edge of understanding how transcription may go awry in hematopoiesis. APL is characterized by the accumulation of hematopoietic progenitors blocked at the promyelocyte stage of differentiation and is associated with chromosomal translocations that fuse either PML, PLZF, NuMA, NPM or STAT5b with the DNA ligand-binding domain of the RARa (Sirulnik et al., 2003) . The PML-RARa fusion protein generated by the t(15;17) translocation is expressed in over 95% of APL cases, and treatment of this AML subtype (FAB M3) is widely accepted as a paradigm for differentiation therapy based on the reversal of epigenetic marks (Goddard et al., 1991; Vitoux et al., 2007) .
In the context of normal hematopoiesis, RARa, which is highly expressed in granulocytes, acts as a bifunctional modulator of myelopoiesis depending on the binding of cognate ligand (RAR can be activated by all-trans RA or 9-cis RA, whereas RXRs are activated by 9-cis RA alone) (Kastner et al., 2001; Zhu et al., 2001) . In the absence of RA, RARa/RXR heterodimers recruit nuclear co-repressors NCoR and SMRT, which in turn bind HDACs, leading to the establishment of repressive chromatin structure at specific target genes and inhibition of granulocytic differentiation. Physiological concentrations of RA (10 À8 M) trigger the release of repressive HDAC complexes and allow the recruitment of HAT co-activator complexes (including p300, P/CAF and CBP) to target genes, resulting in transcriptionally permissive chromatin structure, gene activation and granulocytic differentiation.
The PML-RARa fusion protein acts as a dominantnegative RAR by recruiting chromatin-modifying activities to target promoters, leading to the constitutive and RA-insensitive repression of RARa target genes. This enhanced repression is mediated by PML-RARa oligomers, which are tightly bound through the coiled-coil domain of PML and are capable of binding DNA independently of RXR (He et al., 1998; Minucci et al., 2000) . PML-RARa oligomers form high-affinity complexes with HDACs and DNMTs, leading to hypoacetylated histones, DNA methylation and transcriptional silencing of target promoters. This functional association between PML-RARa, HDACs, DNMT1 and DNMT3A has been well characterized for one such target gene, RARb2, which encodes a putative tumor suppressor (Di Croce et al., 2002) . Indeed, RARb2 is not expressed in PML-RARa expressing APL blasts and cell lines, and this correlates with promoter hypermethylation, suggesting that silencing of RARb2 may be important for leukemic progression. Following RARb2 promoter hypermethylation, the methyl-CpG-binding protein, MBD1, is subsequently recruited to the promoter via interactions with HDAC3, where it is required for maintained silencing (Villa et al., 2006) . Strikingly, however, treatment of patients with pharmacological doses of all-trans retinoic acid (ATRA, 10 À6 M) causes the release of PML-RARa HDAC-associated corepressor complexes and promotes differentiation of APL blasts, giving rise to the concept that t(15;17) APL is a 'druggable' form of leukemia (Grignani et al., 1998) . The dominant-negative effect of PML-RARa on RARa transcriptional regulation is unlikely to represent the full spectrum of effects mediated by PML-RARa and the reciprocal RARa-PML fusion transcripts. Indeed, a recent study identified a novel PML-RARa transcript lacking the functional domains of RARa in a patient who did not respond typically to ATRA treatment, suggesting that the effect of PML-RARa may be through interference of PML function (Zayed et al., 2007) . The effects of RA may be also be attributed to its ability to alter DNA methylation, since treatment of APL blasts with RA led to reduced DNMT1, DNMT3A and DNMT3B expression and activity, associated with demethylation of RARb2 and differentiation of leukemic blasts (Fazi et al., 2005) .
Acute promyelocytic leukemia fusion proteins also affect histone methylation. A recent study by Carbone et al. (2006) revealed that PML-RARa interacts with SUV39H1, the mammalian ortholog of Drosophila Su(var)3-9, which belongs to a family of SET-domain, chromatin-modifying proteins. Recruitment of SUV39H1 to the RARb2 promoter in PML-RARa overexpressing cells was associated with H3K9 trimethylation, a marker of heterochromatin and accompanied by strong transcriptional repression. Furthermore, the association of PML-RARa with SUV39H1 significantly inhibited vitamin D and transforming growth factor-b (TGFb)-induced differentiation in the U937 cells, suggesting that the oncogenic properties of the PML-RARa fusion are linked to its ability to stably silence genes required for myeloid differentiation by recruitment of specific chromatin-modifying activities.
In addition to recruiting DNMTs, HDACs and HMTs, recent studies reveal that PML-RARa is also capable of recruiting the polycomb repressive complexes 2, 3 and 4 (PRC2/3/4) to RARb2 and NFE-2 target promoters (Villa et al., 2006) . PML-RARa co-purified with several components of the PRC multiprotein complex including SUZ12 and EZH2, a HMTase specific for H3K27 and H1K26, and transcriptional repression correlated with an increase in H3K27 trimethylation. Importantly, knockdown of SUZ12 in the NB4 APL cell line, which overexpresses the PML-RARa fusion, induced differentiation, suggesting that the oncogenic block induced by PML-RARa may be via PRC-mediated repression of specific target genes. The interaction of PML-RARa with PRC2/3/4 was through the PML portion of the fusion, and wild-type PML but not RARa, was capable of binding PRC2/3/4. Taken together, these results suggest that the normal function of PML may be the repression of specific target genes (for example, HOX genes which are targets of PcG proteins) via interactions with PRC complexes, a function that may be disrupted in t(15;17), and indeed overexpression of HOX genes is a hallmark of many leukemias. In addition, aberrant repression of RARa targets by PML-RARa-PRC2/3/4 oligomers is also likely to be a contributory factor in the leukemic transformation induced by this oncogenic fusion.
Although the details of histone code are now unraveling, the interplay between histone deacetylation, DNA methylation and histone tail methylation is not completely understood. It is known that certain epigenetic modifications precede others, for example, H3K9 methylation requires prior deacetylation of the same lysine residue, however the exact sequence of events culminating in PML-RARa-mediated repression at the RARb2 promoter remains elusive. Indeed, demethylating agents were not sufficient to completely rescue the PML-RARa/SUV39H1-induced differentiation block in U937 cells, while a partial release was observed in SUV39H1 overexpressing cells, suggesting that both modifications are involved in the transcriptional programs blocking myeloid differentiation. It is likely that the degree of repression mediated by PMLRARa-chromatin-modifying complexes differs for individual target genes and is also subject to regulation by different stimuli. To date, a number of PML-RARa target genes with important roles in cellular proliferation and differentiation have been identified including Hox genes (Kim et al., 2005) , C/EBPb (Duprez et al., 2003) , TNFR2 (Park et al., 2003) and RARb2 (Carbone et al., 2006) , however the identification of additional direct targets which may be used as models for PML-RARa-induced chromatin modifications is necessary. The importance for such screens is highlighted by studies demonstrating the unique structure of PML-RARa oligomers that allow the recognition of novel binding sites, in addition to the canonical RAREs, suggesting that the functions of PML-RARa may also be related to the acquisition of new target gene specificities (Kamashev et al., 2004; Zhou et al., 2006) . In addition, the ability of PML-RARa to interact with other HMTs including G9a, hDOT1L, MMSET as well as the recently discovered HDMs including LSD1 and the JmjC domain-containing proteins, will also be of interest and may provide insights into the specificity of PML-RARa and other leukemic oncoproteins. Such studies are crucial to lay the foundations for the development of specific HMT and HDM inhibitors that may be used to increase the efficacy of combinatorial epigenetic-targeted treatments including RA, HDAC inhibitors and DNA demethylating agents.
Epigenetics open questions and therapeutic possibilities
During the past decade the understanding of the molecular mechanisms of epigenetic regulation in normal and malignant development has greatly increased but many questions remain. Some of these include the importance and timing of interplay between DNA methylation, histone methylation and histone acetylation, the role of small RNAs in epigenetic regulation of mammalian genes, the full significance of ubiquitin, SUMO and other chromatin modifications, some of which may yet to be discovered, the relative importance of epigenetic marks in promoters versus the body of a gene and the possibility of an active DNA demethylase.
Epigenetic signals represent the final outcome in a transcriptional hierarchy mediated by transcription factors, and the ability to manipulate these marks and potentially reprogram cancerous cells yields exciting therapeutic possibilities. The use of specific compounds to target aberrant transcription factor/co-repressor interactions or histone-modifying activities represents a logical extension of the past decade's research in elucidating aberrant gene regulation mechanisms. For example, the targeted disruption of Bcl6 and its associated co-repressor SMRT using inhibitor peptides caused growth arrest and apoptosis of Bcl6-expressing lymphoma cells, without affecting normal cells, paving the way for future studies to identify novel peptides capable of specifically inhibiting other oncogenic transcription factors (Polo et al., 2004) . HDAC inhibitors are already approved for cutaneous T-cell lymphoma and at least under some conditions these agents may modulate gene expression to yield a clinical effect (Gore et al., 2006) . HMTs, HDMs and ATP-dependent chromatin remodeling enzymes all remain potential therapeutic targets, but whether inhibition of these enzymes will specifically target the cancer cell in vivo remains to be determined.
